Who is sponsoring NCT05569915?

NCT05569915 is sponsored by Syracuse University.

What drugs are being tested in NCT05569915?

Interventions in NCT05569915: Trauma Expressive Writing, Stigma Expressive Writing, Control.

What condition does NCT05569915 study?

NCT05569915 studies Stress Disorders, Post-Traumatic, Drinking Heavy.

Is NCT05569915 still recruiting?

NCT05569915 is currently completed. Last updated 20 March 2026.

Last reviewed 2026-03-20 · How we verify

NCT05569915: QueST2023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Project QueST 2023: Queer Survivors of Trauma

Completed NA Last updated 20 March 2026

What this trial tests

NA trial testing Trauma Expressive Writing in Stress Disorders, Post-Traumatic in 131 participants. Completed in 30 November 2024.

Timeline

1 June 2023

Primary endpoint
30 November 2024

30 November 2024

Quick facts

Lead sponsor	Syracuse University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	131
Start date	1 June 2023
Primary completion	30 November 2024
Estimated completion	30 November 2024
Sites	1 location across United States

Drugs / interventions tested

Trauma Expressive Writing
Stigma Expressive Writing
Control

Conditions studied

Stress Disorders, Post-Traumatic — all drugs for Stress Disorders, Post-Traumatic →
Drinking Heavy — all drugs for Drinking Heavy →

Sponsor

Syracuse University

Who can join

18 and older, any sex, with Stress Disorders, Post-Traumatic or Drinking Heavy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to test the initial efficacy of tailored online writing interventions specifically designed for sexual minority women, transgender individuals, and/or nonbinary people to target the primary outcomes: posttraumatic stress disorder (PTSD) symptom severity and hazardous drinking.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Expressive writing treatments to reduce PTSD symptom severity and negative alcohol-related outcomes among trauma-exposed sexual minority women and transgender/nonbinary people: Study protocol for a mixed-method pilot trial.
Scheer JR, Behari K, Schwarz AA, Cascalheira CJ, et al · · 2023 · cited 2× · PMID 37671246 · DOI 10.1016/j.conctc.2023.101197

Verify or expand the search:

Other recruiting trials for Stress Disorders, Post-Traumatic

Currently open trials in the same condition.

NCT07422077 — Impact of ERCS on Perceived Stress in Patients Hospitalized in the Post-resuscitation Rehabilitation Service · NA · recruiting
NCT07010770 — SMART Therapist Training: A Hybrid Factorial-SMART Design · NA · recruiting
NCT06852469 — Computational Assessment of GABA Receptor Modulation in PTSD · Phase 4 · recruiting
NCT06000475 — Enhancing Memory in CPT for PTSD · NA · recruiting
NCT06355284 — Overcontrol and Suicide in PTSD · active not recruiting

Other Syracuse University trials

Trials by the same sponsor.

NCT06698497 — Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance · NA · completed
NCT05988515 — AI-Assisted Treatment for Residual Speech Sound Disorders · NA · recruiting
NCT07215533 — Effects of HIIT vs. TRE on Type 2 Diabetes Risk · NA · recruiting
NCT05929859 — Intensive Speech Motor Chaining Treatment for Residual Speech Sound Disorders · Phase 1, PHASE2 · recruiting
NCT05838950 — HIIT Effects on Cardiometabolic Health · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05569915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Syracuse University
Last refreshed: 20 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05569915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing